David Ford - Intercept Pharmaceuticals Chief Human Resource Officer
Executive
Mr. David A. Ford is Chief Human Resource Officer of the company. He brings over 25 years of experience in a variety of human resources roles across the United States, Europe, Latin America and New Zealand. Prior to joining the Company, Mr. Ford spent nearly 15 years at Sanofi, where he most recently served as Vice President Human Resources for the Sanofi Genzyme global business unit from January 2016 to May 2017. Prior to that role, from November 2011 through December 2015, Mr. Ford served as Vice President Human Resources for the Sanofi North American businesses. Mr. Ford joined the pharmaceutical industry in 2002 as the HR DirectorUnited Kingdom and Republic of Ireland for SanofiSynthelabo since 2017.
| Age | 53 |
| Tenure | 8 years |
| Phone | 646 747 1000 |
| Web | https://www.interceptpharma.com |
David Ford Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Ford against Intercept Pharmaceuticals stock is an integral part of due diligence when investing in Intercept Pharmaceuticals. David Ford insider activity provides valuable insight into whether Intercept Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Intercept Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Intercept Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Ford over two weeks ago Acquisition by David Ford of 107500 shares of Prothena Plc at 14.95 subject to Rule 16b-3 |
Intercept Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0723) % which means that it has lost $0.0723 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6402) %, meaning that it created substantial loss on money invested by shareholders. Intercept Pharmaceuticals' management efficiency ratios could be used to measure how well Intercept Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Intercept Pharmaceuticals currently holds 332.67 M in liabilities with Debt to Equity (D/E) ratio of 411.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Intercept Pharmaceuticals has a current ratio of 3.16, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Intercept Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ram Kamineni | Krystal Biotech | N/A | |
| Jane Baj | PTC Therapeutics | N/A | |
| Thomas Ross | Akero Therapeutics | N/A | |
| Pierre MS | PTC Therapeutics | 39 | |
| PharmD MBA | Madrigal Pharmaceuticals | N/A | |
| Adam Waldman | TG Therapeutics | N/A | |
| David JD | Akero Therapeutics | N/A | |
| Patrick Mayo | Hepion Pharmaceuticals | N/A | |
| Stephane Paquette | Krystal Biotech | N/A | |
| Kathryn Romano | Krystal Biotech | 42 | |
| Tina Ventura | Madrigal Pharmaceuticals | N/A | |
| Christine Wilson | Krystal Biotech | N/A | |
| Clint Wallace | Madrigal Pharmaceuticals | N/A | |
| Murad Husain | PTC Therapeutics | N/A | |
| Emily Hill | PTC Therapeutics | 44 | |
| Meg Dodge | Krystal Biotech | N/A | |
| Don Mankoff | PTC Therapeutics | N/A | |
| Michael Morneau | Viking Therapeutics | 60 | |
| Lee MD | PTC Therapeutics | 57 | |
| Hege SollieZetlmayer | PTC Therapeutics | N/A | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.64 | |||
| Return On Asset | -0.0723 |
Intercept Pharmaceuticals Leadership Team
Elected by the shareholders, the Intercept Pharmaceuticals' board of directors comprises two types of representatives: Intercept Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Intercept. The board's role is to monitor Intercept Pharmaceuticals' management team and ensure that shareholders' interests are well served. Intercept Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Intercept Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Linda Richardson, Ex Officer | ||
| Andrew Saik, Chief Officer | ||
| David Ford, Chief Human Resource Officer | ||
| Jerome Durso, CEO Pres | ||
| Mark MD, Advisor Founder | ||
| Jared JD, G Counsel | ||
| Rocco Venezia, Chief Treasurer | ||
| Paul Nitschmann, VP Affairs | ||
| Nareg Sagherian, Ex Relations | ||
| MD MPH, Pres Officer |
Intercept Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Intercept Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | |||
| Return On Asset | -0.0723 | |||
| Profit Margin | (0.19) % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 695.84 M | |||
| Shares Outstanding | 41.81 M | |||
| Shares Owned By Insiders | 3.12 % | |||
| Shares Owned By Institutions | 81.30 % | |||
| Number Of Shares Shorted | 10.19 M | |||
| Price To Earning | (3.88) X |
Thematic Opportunities
Explore Investment Opportunities
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Intercept Stock
If you are still planning to invest in Intercept Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intercept Pharmaceuticals' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |